Market Overview

UPDATE: Morgan Stanley Upgrades Medtronic Following Acquisition Of COV

Share:
Related MDT
A Peek Into The Markets: U.S. Stock Futures Surge Ahead Of Earnings
14 Stocks To Watch For November 21, 2017
Medtronic's (MDT) CEO Omar Ishrak on Q2 2018 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis upgraded the rating on Medtronic (NYSE: MDT) from Equal-Weight to Overweight, and named a $73.00 price target.

In the report, Morgan Stanley noted, “We are upgrading MDT to Overweight following its transformational acquisition of COV. The initial muted reaction (-1%) fails to appreciate greater financial upside through cost and tax synergies and peer leading capital deployment flexibility which should drive >10% returns.”

Medtronic closed on Monday at $60.03.

Latest Ratings for MDT

DateFirmActionFromTo
Oct 2017BMO CapitalMaintainsOutperform
Oct 2017Leerink SwannMaintainsMarket Perform
Oct 2017Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!

Partner Center